You searched for "macular"

1822 results found

Specialist high-street eye clinics for managing patients with retinal disorders can enhance care standards

The author examines the successful introduction of community-based retinal clinic services by Manchester University NHS Foundation Trust. Dr Sajjad Mahmood, Consultant Ophthalmologist, MREH, shares experience of establishing community-based medical retina clinic services. Sight loss from age-related macular degeneration (AMD), cataract,...

The effects of anti-VEGF therapy for NvAMD on retinal vasculature

This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...

What’s new in wet AMD papers?

Paper presentations on neovascular (‘wet’) age-related macular degeneration (AMD) from the 16th European Society of Retina Specialists Congress, Copenhagen, September 2016, outline recent research directions evaluating the impact of vision loss on key health domains, patient preferences in the process...

The management of retinal vein occlusions: a summary

Retinal vein occlusions (RVO) are the most common cause of visual loss from retinal vascular disease second to diabetic retinopathy. Vision is lost due to ischaemia, macular oedema and / or haemorrhage which ultimately effects a patient’s quality of life...

Outcomes of ‘treat and extend’ for neovascular AMD

The authors report on 24-month outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy using a ‘treat and extend’ regime for treatment-naïve neovascular age-related macular degeneration (nAMD). Data for this study was collected from the Fight Retinal Blindness observational registry based...

Aqueous humour cytokine levels in PCV and nAMD

This study looks into the possible roles of various cytokines or growth factors in the pathogenesis of exudative age-related macular degeneration (AMD) by comparing aqueous levels of 14 cytokines between eyes with polypoidal choroidal vasculopathy (PCV) and those with neovascular...

A tale of two membranes

It was the best of times, it was the worst of times... It was the season of Light, it was the season of Darkness... I am fortunate to work on a vitreoretinal firm at the moment and only a few...

Burning vision: vision loss from misuse of ‘toy’ laser pens in children

A case series of five children with macular burns due to the misuse of novelty laser products, purchased online or abroad, was undertaken at the Royal Hallamshire Hospital and The Children’s Hospital, Sheffield [1]. All patients were from the Sheffield...

Features of AMD treatment non-responders

This is a retrospective consecutive case series of 365 eyes with age-related macular degeneration (AMD) who had three monthly intravitreal aflibercept treatments for at least 12 months. Responders were defined as complete resolution of exudation, intraretinal oedema, subretinal fluid, pigment...

Evaluation of fluocinolone acetonide in the management of BRC

This is a single-centre, retrospective, intervention study of 15 eyes of birdshot retinochoroiditis (BRC) patients who received Iluvein, with a mean follow-up period of 31 months. Five eyes had previously received dexamethasone intravitreal implant 0.7mg (Ozurdex). Fluorescein angiography (FA) showed...

Sustainability in eyecare: Are virtual clinics the way forward in the diagnosis and monitoring of retinal disease?

Virtual clinics can be used successfully in screening and management of ocular conditions such as diabetic retinopathy, retinopathy of prematurity and age-related macular degeneration. Virtual clinics should be a considered as a more clinically appropriate modality of consultation, diagnosis and...

Neovascular AMD: fresh recommendations underline standards of best practice

The management of neovascular age-related macular degeneration (nAMD) has advanced dramatically over the past seven years, with the introduction of targeted new therapies that successfully maintain or improve vision in a majority of affected individuals. It’s a fast moving field,...